Earnings per Share (EPS) (Basic): A company's net earnings or losses attributable to common shareholders per basic share basis.
Relmada Therapeutics, Inc. (RLMD) had Earnings per Share (EPS) (Basic) of $-0.30 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-10.09M |
|
-- |
|
-- |
|
$10.33M |
|
$-10.33M |
|
$0.24M |
|
$-10.09M |
|
$-10.08M |
|
$-10.09M |
|
$-10.09M |
|
$-10.09M |
|
$-10.08M |
|
$-10.33M |
|
$-10.33M |
|
33.19M |
|
33.19M |
|
|
Earnings per Share (EPS) (Basic) |
$-0.30 |
$-0.30 |
|
| Balance Sheet Financials | |
$14.85M |
|
-- |
|
$0.02M |
|
$14.88M |
|
$5.19M |
|
-- |
|
$0.22M |
|
$5.41M |
|
$9.47M |
|
$9.47M |
|
$9.47M |
|
33.19M |
|
| Cash Flow Statement Financials | |
$-31.19M |
|
$28.79M |
|
$-0.07M |
|
$3.86M |
|
$1.38M |
|
$-2.47M |
|
$11.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-31.19M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-106.61% |
|
-106.61% |
|
-67.84% |
|
-106.61% |
|
$0.29 |
|
$-0.94 |
|
$-0.94 |
|